Clinical trials: Treatment Resistant Depressive Disorder
Depressive Disorder, Treatment-Resistant
An Epidemiology Study of Treatment Resistant Depression in the United States (US)
The purpose of this study is to describe the epidemiology of Treatment Resistant Depression (TRD) in the US, including the population incidence of TRD, and TRD as a proportion of Pharmacologically Treated Depression (PTD), and…
- Trial name
- NCT03109002
- Volunteers
- 200,000 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
Evaluation of Schemes of Administration of Intravenous Ketamine in Depression
Mexico, prevalence reported for major depressive disorder (MDD) is of 7.2%. It is currently in the top 5 causes of disability worldwide.
- Trial name
- NCT03742557
- Testing
- Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurology and Neurosurgery, Mexico
Treatment Resistant Depression, Major Depressive Disorder
pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression
Investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DMPFC for patients with treatment-resistant depression
- Trial name
- NCT05948839
- Testing
- active rTMS treatment
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Changping Laboratory
Treatment Resistant Depression, Major Depressive Disorder
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT02522377
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Major Depressive Disorder
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
The purpose of this study is to assess the efficacy of a Deep Shaped-Field repetitive transcranial magnetic stimulation (DSF-rTMS) system in the treatment of depression.
- Trial name
- NCT01431001
- Testing
- Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
- Where
- 4 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Cervel Neurotech, Inc.
Major Depression
TBS Over DLPFC in Elderly Refractory Depression
The study aim to examine the effect of Thea-burst stimulation over bilateral dorsolateral prefrontal cortex (DLPFC) among patients with LLD on mood condition and relevant biomarkers.
- Trial name
- NCT04872465
- Testing
- TBS
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Depression, Major Depressive Disorder
Reward Emotion Learning and Ketamine Study
Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described.
- Conditions
- Depression, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- RELAKS (NCT04850911)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
- Trial name
- NCT04433845
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sheppard Pratt Health System
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Late Life Depression
A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression
Late-life depression affects 2-8% of seniors and causes high rates of caregiver distress and risk of suicide. To exacerbate the problem, antidepressants, the cornerstone of therapy, are resistant in 55-80% of this population.
- Trial name
- NCT03368560
- Testing
- Sudarshan Kriya Yoga
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Depressive Disorder,, Treatment-Resistant Depression
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population.
- Trial name
- NCT01868802
- Testing
- Ketamine
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Paul J. Lamothe
Treatment Resistant Depression
Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement
The study will examine the autonomic, physiologic and neurophysiologic effects of implanted Vagus Nerve Stimulation (VNS) in treatment-resistant depression patients.
- Trial name
- NCT07310381
- Testing
- Vagus Nerve Stimulation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Treatment Resistant Depression (TRD)
Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression
The trial utilizes a pragmatic, randomized, open label design with two parallel arms. Participants aged 18-65 with a diagnosis of unipolar depressive disorder and without stable remission in the past 12 months are randomized 1:1…
- Trial name
- NCT07080723
- Testing
- Algorithm guided treatment (AGT), Treatment as usual (TAU)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Aalborg University Hospital
Major Depression
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
Background: Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences.
- Trial name
- NCT02484456
- Testing
- AV 101 (4-Chlorokynurenine)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment-Resistant Major Depressive Disorder, Major Depressive Disorder
Precision Closed-loop Brain-Computer Interface Neuromodulation for Treatment-Resistant Depression
The goal of this clinical trial is to evaluate whether precision closed-loop neuromodulation treatments can improve depressive symptoms and daily functioning in people with treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT07783906
- Testing
- Closed-loop Deep Brain Stimulation (DBS), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- Volunteers
- 70 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or…
- Trial name
- NCT00231335
- Testing
- escitalopram
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Resistant Depression, Moods Disorders
tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients
The aim is to investigate the effect of transcranial Direct Current Stimulation (tDCS) applied at the anodal left CDLPF of patients with resistant depression compared to patients treated with conventional therapy.
- Conditions
- Resistant Depression, Moods Disorders, Unipolar Depression, Bipolar Disorder
- Trial name
- STICODEP (NCT01644747)
- Testing
- transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
- Where
- 6 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Depression, Inflammation
Tofacitinib in Depression (TIDE)
This study will test whether 7-10 day administration of the anti-inflammatory drug, tofacitinib, has positive effects on people experiencing treatment-resistant depression compared to placebo.
- Trial name
- TIDE (NCT04141904)
- Testing
- Tofacitinib 5 MG [Xeljanz]
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- University of Oxford
Bipolar Disorder I, Bipolar II Disorder
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness
To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking…
- Conditions
- Bipolar Disorder I, Bipolar II Disorder, Bipolar I Disorder, Bipolar Disorder
- Trial name
- NCT05705063
- Testing
- LCHF Ketogenic Diet
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Treatment Resistant Depressive Disorder
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant depression (TRD).
- Trial name
- NCT05196971
- Testing
- HS-10345 84mg
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.